Processa Pharmaceuticals
PCSA
8 hedge funds and large institutions have $87.5K invested in Processa Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
32% more capital invested
Capital invested by funds: $66.5K → $87.5K (+$21K)
14% more funds holding
Funds holding: 7 → 8 (+1)
0.05% more ownership
Funds ownership: 0.06% → 0.11% (+0.05%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$36.1K |
| 2 |
MMA
Miracle Mile Advisors
Los Angeles,
California
|
+$11.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$8.32K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.57K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.35K |
| 2 |
AF
Allworth Financial
Folsom,
California
|
-$117 |
| 3 |
MIM
Macroview Investment Management
Bethesda,
Maryland
|
-$2 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HF
1
HRT Financial
New York
| $28K | +$36.1K | +1,279 | New |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $21.7K | – | – | – |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $19.6K | +$2.57K | +91 | +12% |
|
|
MMA
4
Miracle Mile Advisors
Los Angeles,
California
| $8.84K | +$11.3K | +400 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $6.99K | +$8.32K | +295 | +1,405% |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $2.18K | -$1.35K | -48 | -33% |
|
7
Wells Fargo
San Francisco,
California
| $136 | – | – | – |
|
8
Bank of America
Charlotte,
North Carolina
| $22 | – | – | – |
|
|
AF
9
Allworth Financial
Folsom,
California
| – | -$117 | -3 | Closed |
|
|
MIM
10
Macroview Investment Management
Bethesda,
Maryland
| – | -$2 | – | – |
|
PCSA Hedge Fund Activity: Q4 2024 in Review
8 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q4 2024, worth a combined $87.5K — up 32% from $66.5K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new PCSA positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.
The largest buyer was HRT Financial, opening a new position worth an estimated $36.1K. The largest seller was Tower Research Capital (TRC), cutting an estimated $1.35K.
- 8 institutional investors held Processa Pharmaceuticals (PCSA) as of Q4 2024, up from 7 in Q3 2024.
- Funds reported $87.5K of Processa Pharmaceuticals stock for Q4 2024, up 32% quarter-over-quarter.
- 2 funds opened new Processa Pharmaceuticals positions in Q4 2024 and 1 closed out, a net change of +1 holder.
- The largest Processa Pharmaceuticals buyer in Q4 2024 was HRT Financial, an estimated $36.1K added.
- The largest Processa Pharmaceuticals seller in Q4 2024 was Tower Research Capital (TRC), an estimated $1.35K sold.
Based on aggregated 13F filings for Q4 2024.